1-{[(3',6'-Dihydroxy-3-Oxo-3H-Spiro[2-Benzofuran-1,9'-Xanthen]-6-Yl)Carbonyl]Oxy}Pyrrolidine-2,5-Dione

Labelling of immunoglobulin G for lateral flow immunoassay conjugate pads and microtitre-plate-based ELISA reagents begins with the selection of 6-carboxyfluorescein succinimidyl ester as the amine-reactive fluorophore, chosen for its extinction coefficient of 83,000 M⁻¹cm⁻¹ at 495 nm (pH 9.0) and a quantum yield of 0.93 that remains sufficiently stable across the physiological pH range used in diagnostic workflows. A 10 mg/mL stock solution in anhydrous N,N-dimethylformamide is freshly prepared inside a nitrogen-purged glove box and added dropwise, with a calibrated positive-displacement pipette, to a 1.0 mg/mL solution of Protein A-purified IgG in 0.1 M sodium bicarbonate buffer that has been pre-chilled to 4 °C and brought to pH 8.3 ± 0.1 using a Mettler Toledo SevenCompact meter. The molar input ratio of dye to protein is strictly controlled between 10:1 and 20:1, with the reaction mixture kept under gentle vortex mixing at 22 ± 2 °C for 2 hours in the dark, as standard laboratory lighting accelerates photobleaching of the fluorescein chromophore and raises background noise in subsequent spectrophotometric analysis. Unreacted ester is quenched by the addition of 1.0 M glycine, pH 7.0, to a final concentration of 50 mM, and free dye plus quenching by-products are removed by size-exclusion chromatography on a Sephadex G-25 resin packed in a GE Healthcare XK 16/20 column, pre-equilibrated with phosphate-buffered saline at pH 7.4, using an ÄKTA pure 25 system operated at a linear flow rate of 1.0 mL/min as recommended by the resin manufacturer’s residence-time distribution data. The conjugate peak eluting at 0.42–0.48 column volumes is collected, concentrated to 2.0 mg/mL by tangential-flow filtration through 30 kDa regenerated cellulose membranes (Millipore Pellicon 3 Cassette), and buffer-exchanged into the same PBS formulation. Labeling efficiency and the dye-to-protein (F/P) molar ratio are quantified by UV–Vis spectrophotometry on a NanoDrop One instrument, recording absorbance at 280 nm and 495 nm. The F/P ratio is calculated using the established dual-wavelength correction equation A₄₉₅ /(1.4 × A₂₈₀ – 0.35 × A₄₉₅), targeting a final registered value of 2.5–4.5 per conjugate unit; conjugates displaying ratios above 5.0 exhibit measurable self-quenching and reduced immunoreactivity in capture-ELISA validation, whereas those below 2.0 fail to meet the minimum signal-to-noise threshold of 10:1 required by the CLSI guideline I/LA30-A2. The purified conjugate is filtered through a 0.2 µm PVDF membrane and must pass a functional assay where the limit of detection for a nominal target antigen, such as C-reactive protein, is not permitted to exceed 10 pg/mL in a sandwich ELISA format performed on a BioTek Synergy H1 reader. Production-scale processing, conducted inside an ISO Class 7 cleanroom compliant with ISO 13485:2016 Clause 7.3.7 on design and development controls, utilizes jacketed glass reactors with overhead stirring at 100 rpm and automated pH logging via Mettler Toledo InPro 3250 electrodes; every batch is also subject to residual DMF quantification by headspace GC–MS with a reporting limit of 50 ppm as per ICH Q3C (R8). Conjugates packaged in single-use aliquots with 0.1 % sodium azide and stored at -20 °C retain over 95 % of initial immunoreactivity across 12 months, although freeze-thaw cycling beyond three cycles induces aggregate formation that is detectable by dynamic light scattering on a Malvern Zetasizer Nano ZS, with a polydispersity index exceeding 0.30 and a volume-based particle size shifting beyond 25 nm, which signals structural denaturation that prohibits further use in regulated diagnostic devices under FDA 21 CFR 809.10(b).

What analytical parameters govern the use of 6-FAM-labelled cells in flow cytometry? For surface marker profiling, freshly harvested peripheral blood mononuclear cells or cultured cell lines are washed twice in ice-cold Dulbecco’s PBS without Ca²⁺/Mg²⁺, resuspended at a density of 1 × 10⁶ cells/mL, and incubated with the succinimidyl ester prepared as a 0.1 µg/mL working dilution in anhydrous DMSO – immediately before use, owing to the aqueous hydrolysis half-life of the active ester measured at 28 ± 3 min in 0.1 M bicarbonate, pH 8.0 at 25 °C. The conjugation proceeds for 30 minutes at 4 °C in the dark, followed by addition of cold fetal bovine serum to 10 % (v/v) to quench free reactive groups and two washes with PBS containing 1 % BSA. Viability is monitored by propidium iodide exclusion on a BD FACSCanto II flow cytometer, with a forward-scatter threshold set to exclude debris and a viability gate requiring >95 % PI-negative events as described in CLSI guideline H62. A 488 nm argon laser is used for excitation, and fluorescein emission is collected through a 530/30 bandpass filter with fluorescence compensation against phycoerythrin (PE) set at 1.2 % using software-automated compensation matrices. Isotype control antibodies bearing an identical F/P ratio – determined by batch absorbance ratio and verified by SDS-PAGE with UV transillumination – are mandatory to gate non-specific binding, and any shift of the isotype median fluorescence intensity beyond 50 % of the positive population invalidates the run per the laboratory’s quality control rules aligned with FDA 21 CFR 58.63 for nonclinical data integrity. Surface amine reactive labeling is avoided if the target epitope contains lysine residues in the binding pocket, as site-specific modification can lead to loss of antigenicity that is detectable by competition ELISA but not by simple fluorimetry, requiring orthogonal verification with unlabeled competitor.

At the final stage of Fmoc‑based solid-phase peptide synthesis, the N‑terminal protecting group is fully removed using 20 % piperidine in DMF, deprotection completeness being confirmed by UV monitoring of the dibenzofulvene adduct at 304 nm with a threshold of >99 % release, whereafter the resin-bound peptide bearing a single free α‑amine or an orthogonally deprotected lysine ε‑amine is drained and washed four times with anhydrous DMF. A solution of 4 equivalents of 6‑carboxyfluorescein succinimidyl ester, relative to the amine loading, is prepared in the minimum volume of anhydrous DMF containing 2 % (v/v) N,N‑diisopropylethylamine, and is immediately transferred to the sparged peptide-resin slurry. The coupling proceeds in the dark at 25 °C for 4 hours under gentle nitrogen agitation on a Labconco RotoVap‑controlled vortex system. Following repeated washing with DMF, dichloromethane, and again DMF, the labelled peptide is cleaved from the Rink amide or Wang resin using a freshly prepared mixture of trifluoroacetic acid / thioanisole / water (95:2.5:2.5 v/v/v) for 2.5 hours, precipitated in cold diethyl ether, and centrifuged at 5,000 × g for 15 minutes. The ether‑washed pellet is dissolved in 0.1 % TFA in water and purified on a Waters XBridge BEH C18 column (5 µm, 4.6 × 150 mm) with a linear gradient of acetonitrile in 0.1 % TFA running from 10 % to 60 % over 30 minutes at a flow rate of 1.0 mL/min, detection being performed at 230 nm and 495 nm. The fluorescent peptide elutes as a single peak at a retention time corresponding to 35–40 % acetonitrile; product identity is confirmed by ESI‑TOF mass spectrometry with a mass accuracy of <5 ppm, and purity is determined by analytical HPLC to exceed 95 %. Freeze‑dried aliquots stored under argon at -80 °C maintain >90 % purity for 24 months as per stability data generated under ICH Q1A(R2) conditions, and the lyophilised powder is shipped with a certificate of analysis that explicitly states the residual TFA content is below 0.1 % by ion chromatography. This reagent is designated for research use only and labeled accordingly under EU IVDR 2017/746 Article 5 for RUO products, with exclusion from clinical decision-making unless further validation according to ISO 15189:2022 is performed by the end user.

Incorporation of the 6‑carboxyfluorescein fluorophore into oligonucleotides for molecular diagnostic probe construction is accomplished by first synthesising the 5’‑aminohexyl‑modified oligomer on a controlled‑pore glass support using standard phosphoramidite chemistry with a 5’‑Amino‑Modifier C6 phosphoramidite (Glen Research) coupled at the final cycle with an extended coupling time of 300 seconds. Deprotection is carried out with a 1:1 mixture of 30 % ammonium hydroxide and 40 % aqueous methylamine at 65 °C for 15 minutes (AMA protocol), and the crude product is purified by anion‑exchange HPLC on a DNAPac PA200 column, followed by desalting on a Sephadex G‑25 nap‑column. The amino‑functionalised oligonucleotide is dried in a vacuum concentrator, resuspended in 0.1 M sodium borate buffer pH 8.5, and a 50‑fold molar excess of 6‑FAM NHS ester, freshly dissolved in DMSO to a concentration of 20 mg/mL, is added in a single portion. The reaction mixture is incubated for 16 hours at 25 °C in the dark, quenched with 0.1 M glycine for 30 minutes, and precipitated with 3 volumes of cold absolute ethanol in the presence of 0.3 M sodium acetate. The pellet is washed with 70 % ethanol, dried, and further purified by reversed‑phase HPLC on a C18 column using a triethylammonium acetate‑acetonitrile gradient; the product peak collected at 260 nm and 495 nm is quantified spectrophotometrically using a conversion factor that accounts for the molar extinction coefficient of the dye at 260 nm (~21,000 M⁻¹cm⁻¹) subtracted from the total absorbance to yield the true oligonucleotide concentration. A minimum labeling efficiency of 85 %, as measured by peak‑area integration, is required for release, and the melting temperature of the probe hybridized to its target is measured by UV thermal denaturation on a Cary 3500 spectrophotometer, with an allowable Tm shift not exceeding 2.0 °C compared to the unlabeled duplex. Oligonucleotides produced under ISO 13485:2016 for in vitro diagnostic use must comply with CLSI standard MM17‑A2 for genotyping probe design, and lot‑specific documentation includes CE‑capillary electrophoresis purity, residual solvent analysis, and endotoxin testing (<0.5 EU/mg).

Loading of amino‑functionalised silica nanospheres for high‑contrast lateral flow test lines

Silica nanospheres with surface primary amine groups are prepared via a modified Stöber process using tetraethyl orthosilicate and 3‑aminopropyltriethoxysilane in an ethanolic ammonia‑water system, yielding particles with a Z‑average diameter of 150 ± 10 nm and a polydispersity index below 0.10 as determined by dynamic light scattering on a Malvern Zetasizer Ultra. Following centrifugal washing at 20,000 × g for 30 minutes and resuspension in anhydrous DMF, the particle suspension is reacted with a 200‑fold excess of 6‑carboxyfluorescein NHS ester relative to the total surface amine content, which is pre‑quantified by a ninhydrin‑based colorimetric assay calibrated with 3‑aminopropylsilane standards. The conjugation proceeds at 25 °C under continuous shaking at 300 rpm for 6 hours in the dark, after which excess dye is removed by three cycles of centrifugation and dispersion in DMF:water (1:1), then three additional cycles in PBS. The final suspension is passed through a 0.45 µm filter and stored at 4 °C protected from light. The number of fluorophores per particle is determined by dissolving an aliquot in 0.5 M NaOH, measuring fluorescence against a free 6‑carboxyfluorescein standard curve, and relating to the particle concentration obtained by the dry‑mass method; a loading of 150–200 dye molecules per sphere is targeted. Product release requires a dye‑leaching test where, after 24 hours in PBS at 37 °C, the supernatant fluorescence corresponds to less than 5 % of the total incorporated dye. Conjugates are incorporated on polyester conjugate pads via airbrush deposition at a jet flow of 0.8 µL/cm onto lateral flow strips assembled under ISO 13485‑controlled conditions, and the strips must demonstrate a visible test line signal for the target analyte at the clinically relevant cutoff of 1.0 ng/mL, with the line intensity quantified by a Qiagen ESEQuant reader and required to exceed a threshold of 20 mV when compared to a blank pad.

Fluorescein‑labelled hydrogels for three‑dimensional cell encapsulation and degradation tracking are produced by first synthesising a poly(ethylene glycol)‑amine prepolymer through the reaction of PEG‑diamine (Mw 3400 Da) with acrylic acid N‑hydroxysuccinimide ester, then partially conjugating 1 mol % of the amine groups with 6‑carboxyfluorescein NHS ester in anhydrous dimethyl sulfoxide containing 1 % triethylamine for 2 hours at 25 °C. The degree of substitution is controlled to produce a fluorophore density that does not exceed one fluorescein moiety per 10,000 Da of prepolymer, as higher loading results in concentration quenching that reduces the quantum yield below 0.4 and confounds the linearity of the fluorescence‑strain relationship. The labelled prepolymer is dialysed against deionised water in 7000 Da MWCO tubing, lyophilised, and redissolved in photoinitiator‑containing buffer before photopolymerisation under 365 nm light at 10 mW/cm² for 30 seconds. Cylindrical hydrogel constructs of 6 mm diameter are formed and placed in a cell culture incubator at 37 °C, 5 % CO₂, where the fluorescence intensity is monitored over 14 days using a plate reader at Ex/Em 490/520 nm. Degradation rates, calculated from the loss of fluorescence normalised to the initial wet weight, are accepted only if the coefficient of variation between triplicates is below 15 %. For in‑vitro cytotoxicity, the final hydrogel is tested according to ISO 10993‑5:2009 using L929 murine fibroblasts with an extract dilution method, and a cell viability of >80 % relative to the blank control is required before the material can be released for biomedical research applications. Residual DMSO is kept below 50 ppm as confirmed by headspace GC‑MS, and the dry gel is accompanied by a statement of compliance with REACH regulation (EC) No 1907/2006 for import into the European Union.